Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.38Same Quarter Last Year
Strong Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 13, 2025
|% Change Since: -11.11%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant advancements in Allogene's CAR T programs, notably in large B cell lymphoma and autoimmune diseases. While there are financial losses and some strategic uncertainties, the overall sentiment is bolstered by strong trial progress and financial positioning.Company Guidance
In the call, Allogene Therapeutics provided robust guidance for 2025, highlighting several key metrics. The company expects a cash burn of approximately $170 million and anticipates full-year GAAP operating expenses to be around $250 million, including an estimated non-cash stock-based compensation expense of $50 million. Their financial position by the end of 2024 was strong, with $373.1 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2026. Research and development expenses for the fourth quarter of 2024 were $45 million, bringing the full-year total to $192.3 million. General and administrative expenses for the same period were $15.5 million, with full-year expenses at $65.2 million. The net loss for 2024 amounted to $257.6 million or $1.32 per share. These financial strategies underpin the company's ongoing initiatives in advancing their pipeline and strategic objectives, including their pioneering programs in large B cell lymphoma, autoimmune disease, and renal cell carcinoma.Pivotal Phase II ALLO-501A Trial Progress
The ALLO-501A trial in large B cell lymphoma is advancing with 40 sites activated, showing strong community and academic enthusiasm. Anticipated key milestones include lymphodepletion selection and futility analysis by mid-2025.
Expansion into Autoimmune Diseases with ALLO-329
ALLO-329 received FDA clearance for Phase I trials, marking Allogene's official expansion into autoimmune diseases. The dual-targeting CAR T product candidate could potentially eliminate the need for lymphodepletion.
Encouraging Phase I Data for ALLO-316 in Renal Cell Carcinoma
ALLO-316 shows promise in renal cell carcinoma with a 50% best overall response rate. The program is positioned for potential strategic partnerships, with data updates expected mid-2025.
Strong Financial Position
Allogene reported $373.1 million in cash reserves with a cash runway extending into the second half of 2026. The company maintains capital discipline, preparing for strategic growth.
---
ALLO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ALLO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 13, 2025 | $1.89 | $1.94 | +2.65% |
| Nov 07, 2024 | $3.19 | $3.08 | -3.45% |
| Aug 07, 2024 | $2.47 | $2.36 | -4.45% |
| May 13, 2024 | $2.90 | $2.96 | +2.07% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Allogene Therapeutics Inc (ALLO) report earnings?
Allogene Therapeutics Inc (ALLO) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Allogene Therapeutics Inc (ALLO) earnings time?
Allogene Therapeutics Inc (ALLO) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ALLO EPS forecast?
ALLO EPS forecast for the fiscal quarter 2025 (Q1) is -0.29.
---